You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePrednisolone
Accession NumberDB00860  (APRD00197)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]

Structure
Thumb
Synonyms
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
Hydroretrocortine
Metacortandralone
PRDL
Prednisolona
Prednisolonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ak Tate Oph Sus 1%suspension1 %ophthalmicSandoz Canada Incorporated1985-12-312008-08-07Canada
Diopred Suspension 1%suspension1 %ophthalmicSandoz Canada Incorporated1994-12-31Not applicableCanada
Flo-predsuspension15 mg/5mLoralTaro Pharmaceuticals U.S.A., Inc.2008-01-17Not applicableUs
Inflamase Forte Oph Soln 1%liquid10 mgophthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Inflamase Forte Ophthalmic Solution 1%solution1 %ophthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1996-08-202004-07-13Canada
Inflamase Mildliquid.125 %ophthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1995-12-312002-07-04Canada
Inflamase Oph Soln 0.125%liquid1.25 mgophthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Minims Prednisolone Sodium Phosphate 0.5%drops0.5 %ophthalmic; topicalValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
Novo-prednisolone 5mgtablet5 mgoralNovopharm Limited1967-12-312005-08-10Canada
Omnipredsuspension10 mg/mLophthalmicAlcon Laboratories, Inc.2007-11-06Not applicableUs
Orapred ODTtablet, orally disintegrating15 mg/1oralConcordia Pharmaceuticals Inc.2006-06-01Not applicableUs
Orapred ODTtablet, orally disintegrating10 mg/1oralShionogi Inc.2006-06-01Not applicableUs
Orapred ODTtablet, orally disintegrating10 mg/1oralConcordia Pharmaceuticals Inc.2006-06-01Not applicableUs
Orapred ODTtablet, orally disintegrating30 mg/1oralShionogi Inc.2006-06-01Not applicableUs
Orapred ODTtablet, orally disintegrating30 mg/1oralConcordia Pharmaceuticals Inc.2006-06-01Not applicableUs
Orapred ODTtablet, orally disintegrating15 mg/1oralShionogi Inc.2006-06-01Not applicableUs
Pediapredliquid5 mgoralSanofi Aventis Canada Inc1998-09-23Not applicableCanada
Pediapred - Liq 6.7mg/5mlliquid5 mgoralFisons Corporation Ltd.1995-12-311998-08-12Canada
PMS-prednisolonesolution5 mgoralPharmascience Inc2002-03-19Not applicableCanada
PMS-prednisolone Sod Phos Oph Sol Forte 1%drops1 %ophthalmicPharmascience Inc1992-12-31Not applicableCanada
Pred Fortesuspension/ drops10 mg/mLophthalmicAllergan, Inc.1973-06-01Not applicableUs
Pred Fortesuspension/ drops10 mg/mLophthalmicA S Medication Solutions Llc1973-06-01Not applicableUs
Pred Fortesuspension/ drops10 mg/mLophthalmicA S Medication Solutions Llc1973-06-01Not applicableUs
Pred Forte 1%drops1 %ophthalmicAllergan Inc1974-12-31Not applicableCanada
Pred Mildsuspension/ drops1.2 mg/mLophthalmicPhysicians Total Care, Inc.2012-11-01Not applicableUs
Pred Mildsuspension/ drops1.2 mg/mLophthalmicPreferred Pharmaceuticals, Inc2012-03-05Not applicableUs
Pred Mildsuspension/ drops1.2 mg/mLophthalmicAllergan, Inc.1972-12-01Not applicableUs
Pred Mild 0.12%drops0.12 %ophthalmicAllergan Inc1974-12-31Not applicableCanada
Prednisolone Acetatesuspension/ drops10 mg/mLophthalmicSandoz Inc.1994-12-15Not applicableUs
Prednisolone Acetatesuspension/ drops10 mg/mLophthalmicH.J. Harkins Company, Inc.1997-08-19Not applicableUs
Prednisolone Acetatesuspension/ drops10 mg/1ophthalmicREMEDYREPACK INC.2013-04-12Not applicableUs
Prednisolone Acetatesuspension10 mg/mLophthalmicClinical Solutions Wholesale1994-12-15Not applicableUs
Prednisolone Acetatesuspension/ drops10 mg/mLophthalmicPacific Pharma, Inc.1997-08-19Not applicableUs
Prednisolone Acetatesuspension10 mg/mLophthalmicPhysicians Total Care, Inc.2002-11-04Not applicableUs
Prednisolone Acetatesuspension/ drops10 mg/mLophthalmicPreferred Pharmaceuticals, Inc.2012-10-23Not applicableUs
Prednisolone Acetate Ophthalmic Suspension USP 1%suspension1 %ophthalmicBausch & Lomb Pharmaceuticals Inc.Not applicableNot applicableCanada
Prednisolone Sodium Phosphatetablet, orally disintegrating30 mg/1oralPrasco Laboratories2015-10-21Not applicableUs
Prednisolone Sodium Phosphatesolution5 mg/5mLoralSeton Pharmaceuticals, Llc2013-10-18Not applicableUs
Prednisolone Sodium Phosphate 1% Fortedrops; liquid1 %ophthalmicRivex Ophthalmics Inc.1997-05-072003-07-28Canada
Prednisolone Sodium Phosphate ODTtablet, orally disintegrating15 mg/1oralPrasco Laboratories2015-10-21Not applicableUs
Prednisolone Sodium Phosphate ODTtablet, orally disintegrating10 mg/1oralPrasco Laboratories2015-10-21Not applicableUs
R.O.-predphate Tm Fortedrops; liquid1 %ophthalmicRichmond Pharmaceuticals Inc.1992-12-311997-08-11Canada
Ratio-prednisolonesuspension1 %ophthalmicTeva Canada Limited1986-12-31Not applicableCanada
Sab-prednasesolution1 %ophthalmicSabex IncNot applicableNot applicableCanada
Sandoz Prednisolonesuspension0.12 %ophthalmicSandoz Canada Incorporated1993-12-31Not applicableCanada
Sandoz Prednisolonesuspension1 %ophthalmicSandoz Canada Incorporated1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Millipredsolution10 mg/5mLoralLaser Pharmaceuticals, LLC2009-07-01Not applicableUs
Millipredtablet5 mg/1oralZylera Pharmaceuticals, LLC2014-03-01Not applicableUs
Millipredtablet5 mg/5mgoralLaser Pharmaceuticals, LLC2008-10-01Not applicableUs
Millipredsolution10 mg/5mLoralZylera Pharmaceuticals, LLC2014-03-01Not applicableUs
Orapredsolution15 mg/5mLoralShionogi Inc.2000-12-142016-02-22Us
Pediapredsolution5 mg/5mLoralRoyal Pharmaceuticals2003-03-26Not applicableUs
Prednisolonesolution15 mg/5mLoralTeva Pharmaceuticals USA Inc1998-12-11Not applicableUs
Prednisolonesyrup15 mg/5mLoralEthex Corporation2004-05-10Not applicableUs
Prednisolonesyrup15 mg/5mLoralQualitest Pharmaceuticals2007-09-21Not applicableUs
Prednisolonesolution15 mg/5mLoralProficient Rx LP2003-02-27Not applicableUs
Prednisolonesolution15 mg/5mLoralAidarex Pharmaceuticals LLC1998-12-11Not applicableUs
Prednisolonesyrup15 mg/5mLoralPhysicians Total Care, Inc.2003-02-28Not applicableUs
Prednisolonesyrup15 mg/5mLoralPreferred Pharmaceuticals, Inc.2013-10-25Not applicableUs
Prednisolonesyrup5 mg/5mLoralPhysicians Total Care, Inc.2003-02-28Not applicableUs
Prednisolonesolution15 mg/5mLoralDIRECT RX2014-01-01Not applicableUs
Prednisolonesolution15 mg/5mLoralApotheca Inc.2003-02-27Not applicableUs
Prednisolonesolution15 mg/5mLoralPreferred Pharmaceuticals, Inc2003-02-27Not applicableUs
Prednisolonesolution15 mg/5mLoralHi Tech Pharmacal Co., Inc.2003-02-27Not applicableUs
Prednisolonesolution15 mg/5mLoralDispensing Solutions, Inc.2003-02-27Not applicableUs
Prednisolonesyrup15 mg/5mLoralClinical Solutions Wholesale2007-09-21Not applicableUs
Prednisolonesolution15 mg/5mLoralStat Rx USA2003-02-27Not applicableUs
Prednisolonesolution15 mg/5mLoralRebel Distributors Corp2003-02-27Not applicableUs
Prednisolonesolution15 mg/5mLoralMed Vantx, Inc.1998-12-11Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralCardinal Health2004-10-04Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralAtlantic Biologicals Corps2005-05-25Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralAmneal Pharmaceuticals of New York, LLC2009-12-01Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralRebel Distributors Corp2009-12-01Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralPhysicians Total Care, Inc.2005-03-03Not applicableUs
Prednisolone Sodium Phosphatetablet, orally disintegrating30 mg/1oralMylan Pharmaceuticals Inc.2014-12-08Not applicableUs
Prednisolone Sodium Phosphatesolution/ drops10 mg/mLophthalmicMwi/Vet One1994-07-29Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralProficient Rx LP2005-04-25Not applicableUs
Prednisolone Sodium Phosphatesolution/ drops10 mg/mLophthalmicBausch & Lomb Incorporated1994-07-29Not applicableUs
Prednisolone Sodium Phosphatetablet, orally disintegrating15 mg/1oralMylan Pharmaceuticals Inc.2014-12-08Not applicableUs
Prednisolone Sodium Phosphatesolution5 mg/5mLoralSeton Pharmaceuticals2003-03-26Not applicableUs
Prednisolone Sodium Phosphatetablet, orally disintegrating10 mg/1oralMylan Pharmaceuticals Inc.2014-12-08Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralUnit Dose Services2005-04-25Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralMorton Grove Pharmaceuticals, Inc.2004-10-04Not applicableUs
Prednisolone Sodium Phosphatesolution/ drops10 mg/mLophthalmicButler Animal Health Supply1994-07-29Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralPharmaceutical Associates, Inc.2005-04-25Not applicableUs
Prednisolone Sodium Phosphatesolution5 mg/5mLoralHi Tech Pharmacal Co., Inc.2003-03-26Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralQualitest Pharmaceuticals2009-05-26Not applicableUs
Prednisolone Sodium Phosphate Oral Solutionsolution25 mg/5mLoralMission Pharmacal Company2012-10-01Not applicableUs
Veripred 20solution20 mg/5mLoralZylera Pharmaceuticals, LLC2014-08-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Ak-PredNot Available
Decortin HNot Available
Delta-CortefNot Available
DeltacortrilNot Available
HydeltraNot Available
Hydeltra-TBANot Available
HydeltrasolNot Available
InflamaseNot Available
Key-PredNot Available
KlismacortNot Available
MeticorteloneNot Available
PanafcorteloneNot Available
PrecortalonNot Available
PredonineNot Available
PreloneNot Available
SoloneNot Available
SteroloneNot Available
UltracortenolNot Available
Brand mixtures
NameLabellerIngredients
BlephamideAllergan, Inc.
Blephamide Oph OntAllergan Inc
Blephamide Opht SuspensionAllergan Inc
Dioptimyd OintmentDioptic Pharmaceuticals Inc
Dioptimyd SuspensionDioptic Pharmaceuticals Inc
Metimyd Oph SusSchering Plough Canada Inc
Odan-cideOdan Laboratories Ltd
Pred-GAllergan, Inc.
Sulfacetamide Sodium and Prednisolone Sodium PhosphateRebel Distributors Corp
Vasocidin Ophthalmic SolutionIolab Pharmaceuticals
Salts
Name/CASStructureProperties
Prednisolone acetate
Thumb
  • InChI Key: LRJOMUJRLNCICJ-JZYPGELDSA-N
  • Monoisotopic Mass: 402.204238692
  • Average Mass: 402.4807
DBSALT000254
Prednisolone sodium phosphate
125-02-0
Thumb
  • InChI Key: VJZLQIPZNBPASX-WFFZFITINA-L
  • Monoisotopic Mass: 484.123893702
  • Average Mass: 484.3876
DBSALT000785
prednisolone sodium succinate
ThumbNot applicableDBSALT001634
Prednisolone tebutate
7681-14-3
Thumb
  • InChI Key: HUMXXHTVHHLNRO-KAJVQRHHSA-N
  • Monoisotopic Mass: 458.266838948
  • Average Mass: 458.587
DBSALT000786
Prednisolone tertiary butylacetate
ThumbNot applicableDBSALT001635
Categories
UNII9PHQ9Y1OLM
CAS number50-24-8
WeightAverage: 360.444
Monoisotopic: 360.193674006
Chemical FormulaC21H28O5
InChI KeyInChIKey=OIGNJSKKLXVSLS-VWUMJDOOSA-N
InChI
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.
PharmacodynamicsPrednisolone is a synthetic glucocorticoid used as antiinflammatory or immunosuppressive agent. Prednisolone is indicated in the treatment of various conditions, including congenital adrenal hyperplasia, psoriatic arthritis, systemic lupus erythematosus, bullous dermatitis herpetiformis, seasonal or perennial allergic rhinitis, allergic corneal marginal ulcers, symptomatic sarcoidosis, idiopathic thrombocytopenic purpura in adults, leukemias and lymphomas in adults, and ulcerative colitis. Glucocorticoids are adrenocortical steroids and cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.
Mechanism of actionGlucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.
Related Articles
AbsorptionReadily absorbed by gastrointestinal tract, peak plasma concentration is reached 1-2 hours after administration.
Volume of distributionNot Available
Protein bindingVery high (>90%)
Metabolism

Excreted in the urine as either free or glucoconjugate.

Route of eliminationNot Available
Half life2-3 hours
ClearanceNot Available
ToxicityLD50=500 mg/kg (oral, rat), short-term side effects include high blood glucose levels and fluid retention. Long term side effects include Cushing's syndrome, weight gain, osteoporosis, glaucoma, type II diabetes and adrenal suppression.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Prednisone Action PathwayDrug actionSMP00440
Prednisolone Action PathwayDrug actionSMP00441
Prednisone Metabolism PathwayDrug metabolismSMP00631
Prednisolone Metabolism PathwayDrug metabolismSMP00632
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier+0.9383
Caco-2 permeable-0.5096
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.7847
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7463
CYP450 2C9 substrateNon-substrate0.8496
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9406
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9418
CYP450 2C19 inhibitorNon-inhibitor0.9253
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9095
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.925
Rat acute toxicity1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.95
hERG inhibition (predictor II)Non-inhibitor0.584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Akorn inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Bel mar laboratories inc
  • Schering corp sub schering plough corp
  • Alpharma uspd inc
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • We pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Muro pharmaceutical inc
  • Teva pharmaceuticals usa inc
  • Halsey drug co inc
  • Ferndale laboratories inc
  • Barr laboratories inc
  • Cm bundy co
  • Elkins sinn div ah robins co inc
  • Everylife
  • John j ferrante
  • Heather drug co inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett co inc
  • Marshall pharmacal corp
  • Panray corp sub ormont drug and chemical co inc
  • L perrigo co
  • Phoenix laboratories inc
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Sperti drug products inc
  • Superpharm corp
  • Tablicaps inc
  • Udl laboratories inc
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Pfizer laboratories div pfizer inc
  • Central pharmaceuticals inc
  • Alcon laboratories inc
  • Allergan pharmaceutical
  • Taro pharmaceuticals usa inc
  • Merck and co inc
  • Novartis pharmaceuticals corp
  • Pharmafair inc
  • Alcon universal ltd
  • Bausch and lomb pharmaceuticals inc
  • Sola barnes hind
  • Shionogi pharma inc
  • Ucb inc
  • Amneal pharmaceuticals
  • Paddock laboratories inc
  • Pharmaceutical assoc inc
Packagers
Dosage forms
FormRouteStrength
Dropsophthalmic
Ointmentophthalmic; topical
Suspensionophthalmic
Suspensionoral15 mg/5mL
Liquidophthalmic10 mg
Solutionophthalmic1 %
Liquidophthalmic.125 %
Liquidophthalmic1.25 mg
Solutionoral10 mg/5mL
Tabletoral5 mg/1
Tabletoral5 mg/5mg
Dropsophthalmic; topical0.5 %
Tabletoral5 mg
Suspensionophthalmic10 mg/mL
Liquidoral5 mg
Solutionoral5 mg
Dropsophthalmic1 %
Suspension/ dropsophthalmic10 mg/mL
Suspension/ dropsophthalmic1.2 mg/mL
Dropsophthalmic0.12 %
Ointmentophthalmic
Suspension/ dropsophthalmic
Solutionoral15 mg/5mL
Syruporal15 mg/5mL
Syruporal5 mg/5mL
Suspension/ dropsophthalmic10 mg/1
Solutionoral5 mg/5mL
Solution/ dropsophthalmic10 mg/mL
Tablet, orally disintegratingoral10 mg/1
Tablet, orally disintegratingoral15 mg/1
Tablet, orally disintegratingoral30 mg/1
Solutionoral25 mg/5mL
Drops; liquidophthalmic1 %
Suspensionophthalmic0.12 %
Suspensionophthalmic1 %
Solutionophthalmic
Solution/ dropsophthalmic
Liquidophthalmic
Solutionoral20 mg/5mL
Prices
Unit descriptionCostUnit
Orapred ODT 48 15 mg Dispersible Tablet Box289.42USD box
Pred Forte 1% Suspension 15ml Bottle97.79USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 10ml Bottle72.82USD bottle
Pred Forte 1% Suspension 10ml Bottle68.06USD bottle
Econopred Plus 1% Suspension 10ml Bottle63.44USD bottle
Solu-Medrol Act-O-Vial 1 g/vial61.25USD vial
Solu-Medrol 1 g/vial60.04USD vial
Pediapred 6.7 mg/5ml Solution 120ml Bottle57.77USD bottle
Pred Mild 0.12% Suspension 10ml Bottle44.33USD bottle
Econopred Plus 1% Suspension 5ml Bottle40.99USD bottle
Solu-Medrol Act-O-Vial 500 mg/vial39.96USD vial
Medrol (Pak) 21 4 mg tablet Disp Pack39.3USD disp
Solu-Medrol 500 mg/vial39.17USD vial
Pred Forte 1% Suspension 5ml Bottle37.12USD bottle
Prednisolone sod ph powder36.11USD g
PrednisoLONE Acetate 1% Suspension 15ml Bottle35.46USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 15ml Bottle34.41USD bottle
Pred Mild 0.12% Suspension 5ml Bottle33.98USD bottle
Methylprednisolone Sod Succin. 1 g/vial32.47USD vial
Solu-medrol 1 gm vial24.43USD vial
PrednisoLONE Acetate 1% Suspension 10ml Bottle24.02USD bottle
Solu-medrol (pf) 500 mg vial20.9USD vial
PrednisoLONE Sodium Phosphate 1% Solution 5ml Bottle19.99USD bottle
Methylprednisolone Sod Succin. 500 mg/vial19.48USD vial
PrednisoLONE Acetate 1% Suspension 5ml Bottle15.99USD bottle
Solu-Medrol Act-O-Vial 125 mg/vial15.94USD vial
Solu-medrol 500 mg vial12.9USD vial
Depo-medrol 80 mg/ml vial11.67USD ml
Depo-Medrol 80 mg/ml11.51USD ml
Pred forte 1% eye drops10.32USD ml
Methylprednisolone Acetate 80 mg/ml9.01USD ml
Methylprednisolone Sod Succin. 125 mg/vial8.9USD vial
Depo-Medrol (Preserved) 80 mg/ml8.89USD ml
Orapred odt 30 mg tablet8.34USD tablet
Orapred odt 15 mg tablet7.97USD tablet
Methylprednisolone Acetate (P) 80 mg/ml6.97USD ml
Omnipred 1% eye drops6.78USD ml
Solu-Medrol Act-O-Vial 40 mg/vial6.72USD vial
Depo-medrol 40 mg/ml vial6.41USD ml
Depo-Medrol 40 mg/ml6.01USD ml
Pred Forte 1 % Suspension5.95USD ml
Solu-medrol (pf) 125 mg vial5.83USD vial
Depo-Medrol (Preserved) 40 mg/ml5.75USD ml
Prednisolone ac 1% eye drop5.75USD ml
Prednisol 1% eye drops5.69USD ml
Pred mild 0.12% eye drops5.14USD ml
Medrol 32 mg tablet5.13USD tablet
Methylprednisolone Acetate 40 mg/ml4.71USD ml
Methylprednisolone Acetate (P) 40 mg/ml4.5USD ml
Econopred plus 1% eye drops3.93USD ml
Orapred odt 10 mg tablet3.89USD tablet
Depo-medrol 20 mg/ml vial3.78USD ml
Methylprednisolone Sod Succin. 40 mg/vial3.77USD vial
Prednisolone sod 1% eye drops3.7USD ml
Medrol 16 mg tablet3.5USD tablet
Prednisolone acetate powder3.36USD g
Prednisolone powder3.36USD g
Depo-Medrol 20 mg/ml2.63USD ml
Medrol 8 mg tablet2.3USD tablet
Ratio-Prednisolone 1 % Suspension2.03USD ml
Sandoz Prednisolone Acetate 1 % Suspension2.03USD ml
Pred Mild 0.12 % Suspension2.02USD ml
Medrol 4 mg tablet1.69USD tablet
Medrol 4 mg dosepak1.59USD each
Sandoz Prednisolone Acetate 0.12 % Suspension1.33USD ml
Millipred dp 5 mg dose pack tablet1.18USD tablet
Medrol 2 mg tablet0.84USD tablet
Orapred 15 mg/5 ml solution0.74USD ml
Millipred 5 mg tablet0.59USD tablet
Prelone 15 mg/5 ml syrup0.54USD ml
Prelone 15 mg/5ml Syrup0.47USD ml
PrednisoLONE Sodium Phosphate 15 mg/5ml Solution0.33USD ml
PrednisoLONE Sodium Phosphate 5 mg/5ml Solution0.23USD ml
Prednisolone 5 mg tablet0.14USD tablet
Pediapred 1 mg/ml Liquid0.14USD ml
Pms-Prednisolone 1 mg/ml Liquid0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5178878 No1993-01-122010-01-12Us
US5881926 No1996-03-162016-03-16Us
US6024981 No1998-04-092018-04-09Us
US6071523 No1998-06-032018-06-03Us
US6221392 No1998-04-092018-04-09Us
US6399079 No1998-06-032018-06-03Us
US6656482 No1998-06-032018-06-03Us
US6740341 No1999-11-242019-11-24Us
US7799331 No2008-10-112028-10-11Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point235 °CPhysProp
water solubility223 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.62HANSCH,C ET AL. (1995)
logS-3.21ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.239 mg/mLALOGPS
logP1.66ALOGPS
logP1.27ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity98.49 m3·mol-1ChemAxon
Polarizability38.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Gunther Bellmann, “Process for producing a sterile prednisolone gel.” U.S. Patent US5811417, issued September 22, 1998.

US5811417
General ReferencesNot Available
External Links
ATC CodesA01AC54A07EA01C05AA04D07AA03D07BA01D07CA03D07XA02H02AB06R01AD02R01AD52S01BA04S01BB02S01CA02S01CB02S02BA03S02CA01S03BA02S03CA02V03AB05
AHFS Codes
  • 52:08.08
  • 68:04.00
PDB EntriesNot Available
FDA labelDownload (101 KB)
MSDSDownload (72.6 KB)
Interactions
Drug Interactions
Drug
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Prednisolone.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prednisolone.
AldesleukinPrednisolone may decrease the antineoplastic activities of Aldesleukin.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Prednisolone.
Aluminum hydroxideThe bioavailability of Prednisolone can be decreased when combined with Aluminum hydroxide.
Amphotericin BPrednisolone may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Prednisolone can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Prednisolone can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Prednisolone.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Prednisolone.
BoceprevirThe serum concentration of Prednisolone can be increased when it is combined with Boceprevir.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prednisolone.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednisolone.
Calcium carbonateThe bioavailability of Prednisolone can be decreased when combined with Calcium carbonate.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Prednisolone.
CapromabPrednisolone may decrease effectiveness of Capromab as a diagnostic agent.
CarbamazepineThe serum concentration of Prednisolone can be decreased when it is combined with Carbamazepine.
CarbimazoleThe serum concentration of Prednisolone can be decreased when it is combined with Carbimazole.
CeritinibPrednisolone may increase the hyperglycemic activities of Ceritinib.
ChlorotrianiseneThe serum concentration of Prednisolone can be increased when it is combined with Chlorotrianisene.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Prednisolone.
ClarithromycinThe serum concentration of Prednisolone can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Prednisolone can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin can be decreased when used in combination with Prednisolone.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Prednisolone.
DarunavirThe serum concentration of Prednisolone can be increased when it is combined with Darunavir.
DeferasiroxThe risk or severity of adverse effects can be increased when Prednisolone is combined with Deferasirox.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Prednisolone.
DesmopressinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Desmopressin.
DihydrotestosteronePrednisolone may increase the fluid retaining activities of Dihydrotestosterone.
EnzalutamideThe serum concentration of Prednisolone can be decreased when it is combined with Enzalutamide.
FosaprepitantThe serum concentration of Prednisolone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Prednisolone can be decreased when it is combined with Fosphenytoin.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Prednisolone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisolone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Prednisolone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Prednisolone.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisolone.
IcosapentThe risk or severity of adverse effects can be increased when Prednisolone is combined with Icosapent.
IdelalisibThe serum concentration of Prednisolone can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of Prednisolone.
IndinavirThe serum concentration of Prednisolone can be increased when it is combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Prednisolone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Prednisolone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Prednisolone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Prednisolone.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Prednisolone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisolone.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Prednisolone.
ItraconazoleThe serum concentration of Prednisolone can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Prednisolone can be increased when it is combined with Ketoconazole.
LeflunomideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Leflunomide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Prednisolone.
LopinavirThe serum concentration of Prednisolone can be increased when it is combined with Lopinavir.
Magnesium oxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium oxide.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone.
MethimazoleThe serum concentration of Prednisolone can be decreased when it is combined with Methimazole.
MifepristoneThe therapeutic efficacy of Prednisolone can be decreased when used in combination with Mifepristone.
MitotaneThe serum concentration of Prednisolone can be decreased when it is combined with Mitotane.
NatalizumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Natalizumab.
NefazodoneThe serum concentration of Prednisolone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Prednisolone can be increased when it is combined with Nelfinavir.
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Prednisolone.
NicorandilThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nicorandil.
OxandrolonePrednisolone may increase the fluid retaining activities of Oxandrolone.
PhenobarbitalThe serum concentration of Prednisolone can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Prednisolone can be decreased when it is combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisolone.
PosaconazoleThe serum concentration of Prednisolone can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Prednisolone can be decreased when it is combined with Primidone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Prednisolone.
RifabutinThe serum concentration of Prednisolone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Prednisolone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Prednisolone can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Prednisolone can be increased when it is combined with Ritonavir.
RoflumilastRoflumilast may increase the immunosuppressive activities of Prednisolone.
SaquinavirThe serum concentration of Prednisolone can be increased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Prednisolone.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Prednisolone.
SparfloxacinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Sparfloxacin.
TacrineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Prednisolone.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Prednisolone.
TelithromycinThe serum concentration of Prednisolone can be increased when it is combined with Telithromycin.
TestosteronePrednisolone may increase the fluid retaining activities of Testosterone.
TofacitinibPrednisolone may increase the immunosuppressive activities of Tofacitinib.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prednisolone.
TorasemidePrednisolone may increase the hypokalemic activities of Torasemide.
TrastuzumabTrastuzumab may increase the neutropenic activities of Prednisolone.
TrichlormethiazidePrednisolone may increase the hypokalemic activities of Trichlormethiazide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Prednisolone.
VoriconazoleThe serum concentration of Prednisolone can be increased when it is combined with Voriconazole.
WarfarinPrednisolone may increase the anticoagulant activities of Warfarin.
Food Interactions
  • Avoid alcohol. Avoid caffeine.
  • Take with food to reduce gastric irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT: Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009 Sep;95(18):1502-7. doi: 10.1136/hrt.2009.168971. Epub 2009 May 28. [PubMed:19482847 ]
  2. Boudinot FD, D'Ambrosio R, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986 Oct;14(5):469-93. [PubMed:2879901 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Frey BM, Frey FJ: Estimation of transcortin concentration by measurements of plasma protein-binding of prednisolone and by electroimmunodiffusion. Br J Clin Pharmacol. 1982 Feb;13(2):245-9. [PubMed:6800390 ]
  4. Ko HC, Almon RR, Jusko WJ: Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. Pharm Res. 1995 Jun;12(6):902-4. [PubMed:7667198 ]
  5. Angeli A, Frajria R, De Paoli R, Fonzo D, Ceresa F: Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man. Clin Pharmacol Ther. 1978 Jan;23(1):47-53. [PubMed:563315 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  2. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 23, 2016 01:50